Triptorelin
(Decapeptyl/Trelstar)

The Discovery

Learning from Gonadorelin's Success

Scientists realized that gonadorelin didn't last long enough for medical use—it disappeared from ...

Scientists realized that gonadorelin didn't last long enough for medical use—it disappeared from blood in 90 minutes. Doctors wanted a version that lasted longer. Schally's lab decided to tinker with the structure. They added one extra amino acid and changed one critical piece. This small change made triptorelin stick to the pituitary gland 100 times longer. They weren't looking for a cancer drug. They just wanted gonadorelin to work better for fertility. They had no idea they were creating one of medicine's greatest weapons against prostate cancer.

The Breakthrough

The Discovery of the Paradox

Early clinical tests revealed something strange.

Early clinical tests revealed something strange. When doctors gave triptorelin, testosterone levels first spiked dramatically—sometimes doubling within hours. Then, after a few days, something miraculous happened: testosterone crashed to almost zero. This paradox confused and frightened doctors at first. They realized the spike could hurt cancer patients. A prostate cancer cell is addicted to testosterone. The spike could cause bone pain, paralysis, or worse. But then the complete shutdown happened. Oncologists realized this was the opportunity they'd been waiting for: a way to starve prostate cancer without cutting off the testes surgically.

The Trials

The Flare Phenomenon and Solutions

As more cancer patients received triptorelin, doctors documented the 'flare phenomenon' carefully.

As more cancer patients received triptorelin, doctors documented the 'flare phenomenon' carefully. The testosterone spike happened in the first week. Some patients with widespread cancer experienced severe bone pain during this time. Researchers developed a solution: give patients an anti-androgen drug (like flutamide) for two weeks before starting triptorelin. This blocks testosterone from attaching to cancer cells, making the flare harmless. The anti-androgen protects during the dangerous spike. After the flare passes and testosterone crashes, doctors can stop the blocker. Suddenly, triptorelin became not just safe, but brilliant.

The Crisis

FDA Approval and Expansion

The FDA approved triptorelin (brand name Trelstar) for treating prostate cancer.

The FDA approved triptorelin (brand name Trelstar) for treating prostate cancer. Doctors hailed it as a breakthrough. Unlike surgical castration, triptorelin was reversible: when you stopped the injections, testosterone came back. Triptorelin's success in cancer care opened doors. Researchers tested it for endometriosis (where uterine tissue grows outside the uterus), and it worked brilliantly by stopping estrogen production. They tested it for precocious puberty (children entering puberty too early), and it prevented early sexual development. They tested it for IVF fertility treatment to prevent premature egg release. Every test succeeded. Triptorelin wasn't just a cancer drug—it was a multipurpose hormone tool.

The Legacy

Today: A Revolutionary Standard of Care

Triptorelin is now standard treatment for advanced prostate cancer worldwide.

Triptorelin is now standard treatment for advanced prostate cancer worldwide. Millions of men have received it. Doctors can choose 1-month, 3-month, or 6-month formulations based on patient preference. For women with severe endometriosis, triptorelin is life-changing: it stops the painful growth of uterine tissue. Children with precocious puberty receive triptorelin to pause development until they're older. In IVF clinics, triptorelin controls when eggs release, letting doctors harvest them at exactly the right moment. It's also being studied for other uses: uterine fibroids, fertility preservation before cancer treatment, and even hair loss in women. What started as a tiny chemical modification became one of medicine's most versatile weapons.